N-(2-fluorophenyl)-1-methyl-4,5-diphenyl-1H-imidazole-2-carboxamide | 1443114-42-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-fluorophenyl)-1-methyl-4,5-diphenyl-1H-imidazole-2-carboxamide
• 英文别名: N-(2-fluorophenyl)-1-methyl-4,5-diphenylimidazole-2-carboxamide
• CAS: 1443114-42-8
• 化学式: C₂₃H₁₈FN₃O
• 分子量: 371.414
• InChiKey: WDIIWXZURYFGPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氟苯基异氰酸酯 、 4,5-diphenyl-1-methyl-1H-imidazole 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 N-(2-fluorophenyl)-1-methyl-4,5-diphenyl-1H-imidazole-2-carboxamide
  参考文献：
  名称：

  Synthesis and Metabolic Studies of Host-Directed Inhibitors for Antiviral Therapy

  摘要：

  Targeting host cell factors required for virus replication provides an alternative to targeting pathogen components and represents a promising approach to develop broad-spectrum antiviral therapeutics. High-throughput screening (HTS) identified two classes of inhibitors (2 and 3) with broad-spectrum antiviral activity against ortho- and paramyxoviruses including influenza A virus (IAV), measles virus (MeV), respiratory syncytial virus (RSV), and human parainfluenza virus type 3 (HPIV3). Hit-to-lead optimization delivered inhibitor 28a, with EC50 values of 0.88 and 0.81 mu M against IAV strain WSN and MeV strain Edmonston, respectively. It was also found that compound 28a delivers good stability in human liver S9 fractions with a half-life of 165 min. These data establish 28a as a promising lead for antiviral therapy through a host-directed mechanism.

  DOI：

  10.1021/ml400166b

文献信息

• Synthesis and Metabolic Studies of Host-Directed Inhibitors for Antiviral Therapy
  作者：Terry W. Moore、Kasinath Sana、Dan Yan、Stefanie A. Krumm、Pahk Thepchatri、James P. Snyder、José Marengo、Richard F. Arrendale、Andrew J. Prussia、Michael G. Natchus、Dennis C. Liotta、Richard K. Plemper、Aiming Sun

  DOI：10.1021/ml400166b

  日期：2013.8.8

  Targeting host cell factors required for virus replication provides an alternative to targeting pathogen components and represents a promising approach to develop broad-spectrum antiviral therapeutics. High-throughput screening (HTS) identified two classes of inhibitors (2 and 3) with broad-spectrum antiviral activity against ortho- and paramyxoviruses including influenza A virus (IAV), measles virus (MeV), respiratory syncytial virus (RSV), and human parainfluenza virus type 3 (HPIV3). Hit-to-lead optimization delivered inhibitor 28a, with EC50 values of 0.88 and 0.81 mu M against IAV strain WSN and MeV strain Edmonston, respectively. It was also found that compound 28a delivers good stability in human liver S9 fractions with a half-life of 165 min. These data establish 28a as a promising lead for antiviral therapy through a host-directed mechanism.